Crenolanib (CP-868596)

Crenolanib (CP-868596)

Catalog Number:
L002369453APE
Mfr. No.:
APE-A8307
Price:
$292
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          Crenolanib (CP-868596) is a potent, specific, and orally available inhibitor of PDGFRα, PDGFRβ and FLT3 with inhibitor-binding constant (Kd) of 3.2, 2.1, and 0.74 nM, respectively [1].
          It has been shown that crenolanib is more potent than quizartinib and sorafenib at blocking FLT3 autophosphorylation and causing cytotoxicity [2]. Crenolanib is confirmed to be100-fold more potent than imatinib at suppressing D842V mutation. In addition, it has been reported that crenolanib inhibits PDGFRα D842V mutation rather than V561D mutation, with IC50 value of 10 nM [1]. In EOL-1 cells, crenolanib also inhibits the FIP1L1-PDGFRA fusion kinase activity (IC50=1 nM) and cell proliferation (IC50= 0.2 pM)[1].

          [1] Heinrich MC1, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M.
          Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012 Aug 15;18(16):4375-84.
          [2] Galanis A1, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100.

      • Properties
        • Alternative Name
          CP-868596;CP 868596;CP868596; 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
          CAS Number
          670220-88-9
          Molecular Formula
          C26H29N5O2
          Molecular Weight
          443.54
          Appearance
          A solid
          Purity
          97.42%
          Solubility
          ≥22.2 mg/mL in DMSO; insoluble in H2O; ≥2.5 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Ivey MJ, Kuwabara JT, et al. "Platelet-derived growth factor receptor-α is essential for cardiac fibroblast survival." Am J Physiol Heart Circ Physiol. 2019 Aug 1;317(2):H330-H344. PMID:31125253
          2. Tang L, Dai F, et al. "RhoA/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton." Pharmacol Res. 2018 May 20;133:201-212. PMID:29791873

    We Also Recommend

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.